Key statistics
On Friday, Roche Holding AG (0TDF:LSE) closed at 57.79, -0.99% below its 52-week high of 58.37, set on Feb 04, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 57.79 |
| Low | 57.79 |
| Bid | -- |
| Offer | -- |
| Previous close | 57.57 |
| Average volume | 115.90k |
|---|---|
| Shares outstanding | 6.47bn |
| Free float | 341.17m |
| P/E (TTM) | 22.16 |
| Market cap | 374.51bn USD |
| EPS (TTM) | 2.58 USD |
| Annual div (ADY) | 1.39 USD |
|---|---|
| Annual div yield (ADY) | 2.41% |
| Div ex-date | Mar 28 2025 |
| Div pay-date | May 14 2025 |
Data delayed at least 15 minutes, as of Feb 06 2026 18:07 GMT.
More ▼
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
- [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
- FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
- Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
- Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
- Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
- European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
- Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
- Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
More ▼
